toripalimab

Start here

Report excerpt

The full results of the GASTO-1052A study were published in the Journal for ImmunoTherapy of Cancer (JITC, IF=11.7). Toripalimab consolidation therapy significantly prolonged progression-free survival versus observation in limited-stage small cell lung cancer (LS-SCLC), with a PFS hazard ratio of 0.55.

Excerpted from mp.weixin.qq.com

Coverage timeline

Follow the coverage to see the different angles.

Oct 24

21:00
x.com
Neoadjuvant Toripalimab Combined with Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma: A Multicenter Prospective, Single-Arm, Phase II Clinical Trial. Presented by

Oct 23

Oct 21

20:00
clinicaltrials.gov
Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer

Oct 19

12:40
mp.weixin.qq.com
Toripalimab Consolidation in Limited-Stage Small Cell Lung Cancer: GASTO-1052A Full Results Published in JITC
The full results of the GASTO-1052A study were published in the Journal for ImmunoTherapy of Cancer (JITC, IF=11.7). Toripalimab consolidation therapy significantly prolonged progression-free survival versus observation in limited-stage small cell lung cancer (LS-SCLC), with a PFS hazard ratio of 0.55.

Heat trend for this story

Heat now 17·Peak in the comparable set 32 (Oct 23 21:00)·Change over 24h in the comparable set -19%·Participants now 6

Participants counted6

Heat over time

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.